Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $256.15M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Ardelyx USD 94.47M 30.74M Mar/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
J&J USD 25.4B 89M Sep/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Merck USD 18.1B 1.5B Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.52B 112M Sep/2026
Novartis USD 13.11B 750M Mar/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026